Alpha 2.0
Login Register
» Articles » PMID: 29465709

An Illustration of the Potential Health and Economic Benefits of Combating Antibiotic-Resistant Gonorrhea

Overview
Journal Sex Transm Dis
Specialty Infectious Diseases
Date 2018 Feb 22
PMID 29465709
Citations 14
Authors
Harrell W Chesson
Robert D Kirkcaldy
Thomas L Gift
Kwame Owusu-Edusei Jr
Hillard S Weinstock
Affiliations
Soon will be listed here.
Abstract

Preventing the emergence of ceftriaxone-resistant Neisseria gonorrhoeae can potentially avert hundreds of millions of dollars in direct medical costs of gonorrhea and gonorrhea-attributable HIV infections. In the illustrative scenario we examined, emerging ceftriaxone resistance could lead to 1.2 million additional N. gonorrhoeae infections within 10 years, costing $378.2 million.

Citing Articles

Antimicrobial Resistance in Curable Sexually Transmitted Infections.

Giacani L, Bradshaw C, Muzny C, Graves K, Pasricha S, Jordan S Curr HIV/AIDS Rep. 2025; 22(1):14.

PMID: 39856345 DOI: 10.1007/s11904-025-00722-7.

Vaccine value profile for Neisseria gonorrhoeae.

Lyu Y, Choong A, Chow E, Seib K, Marshall H, Unemo M Vaccine. 2023; 42(19S1):S42-S69.

PMID: 38123397 PMC: 11169088. DOI: 10.1016/j.vaccine.2023.01.053.

Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study.

Ayinde O, Ross J, Jackson L PLoS One. 2023; 18(10):e0292273.

PMID: 37856496 PMC: 10586702. DOI: 10.1371/journal.pone.0292273.

Rapid molecular phenotypic antimicrobial susceptibility test for based on propidium monoazide viability PCR.

Tjandra K, Ram-Mohan N, Abe R, Wang T, Yang S bioRxiv. 2023; .

PMID: 36909582 PMC: 10002740. DOI: 10.1101/2023.03.01.530513.

Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics.

Mubeen B, Ansar A, Rasool R, Ullah I, Imam S, Alshehri S Antibiotics (Basel). 2021; 10(12).

PMID: 34943685 PMC: 8698349. DOI: 10.3390/antibiotics10121473.

References
1.
Chesson H, Pinkerton S . Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr. 2000; 24(1):48-56. DOI: 10.1097/00126334-200005010-00009. View
2.
Turner K, Garnett G . The impact of the phase of an epidemic of sexually transmitted infection on the evolution of the organism. Sex Transm Infect. 2002; 78 Suppl 1:i20-30. PMC: 1765825. DOI: 10.1136/sti.78.suppl_1.i20. View
3.
Handel A, Regoes R, Antia R . The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol. 2006; 2(10):e137. PMC: 1599768. DOI: 10.1371/journal.pcbi.0020137. View
4.
Chesson H, Collins D, Koski K . Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States. Cost Eff Resour Alloc. 2008; 6:10. PMC: 2426671. DOI: 10.1186/1478-7547-6-10. View
5.
Kirkcaldy R, Ballard R, Dowell D . Gonococcal resistance: are cephalosporins next?. Curr Infect Dis Rep. 2011; 13(2):196-204. DOI: 10.1007/s11908-011-0169-9. View